Robotic total knee replacement still conflates hardware, alignment, and technique
The early national comparison of robotic versus conventional total knee replacement for arthritis found no reduction in early revision, with a hazard ratio of 1.03 and a 95% confidence interval from 0.86 to 1.26. That neutral result matters, but the larger methodological problem is more interesting: the robotic cohort was not one uniform intervention. Mako accounted for 74.8% of robotic knee replacements before matching, leaving the pooled estimate to blend together platform design, alignment philosophy, and surgeon-specific soft-tissue handling in a way that obscures what actually drove outcomes.
A machine may guide the cut, but it does not define the entire operation.
Robot-assisted arthroplasty is often discussed as a single category, yet the clinical question is rarely that simple. A platform can improve bone resection precision while leaving the surgeon’s target alignment strategy untouched, and soft-tissue balancing can still vary from one case to another. If revision risk does not fall, that may reflect the fact that better geometric accuracy does not automatically translate into a more durable knee, especially when implant positioning, ligament tension, and load distribution remain partly dependent on intraoperative judgment.
Alignment accuracy improved, but patient benefit stayed harder to prove
Geng et al. reported improved alignment accuracy in a multicentre randomised trial, but knee function and quality-of-life scores did not differ significantly at 6 weeks. Wang et al., using Mako in both groups, found higher 6-month Forgotten Joint Scores and selected KOOS domain scores with functional alignment versus mechanical alignment, but overall KOOS and satisfaction did not differ significantly. These trials point in different directions, yet neither settles the central question because neither compared different robotic platforms. Within-platform findings cannot establish how much benefit came from the robot itself and how much came from the alignment target selected by the surgeon.
The absence of formal interaction testing in Wang et al. leaves the subgroup findings vulnerable to over-interpretation. Functional alignment may produce a better patient experience in selected domains because it seeks to restore knee kinematics closer to the individual’s native anatomy, reducing the need to force all knees toward a neutral mechanical axis. That approach could plausibly improve perceived joint awareness and movement quality. Even so, without a direct platform comparison, the clinical signal cannot be assigned cleanly to robotic assistance rather than to the alignment philosophy embedded in the procedure.
Larger randomized trials did not rescue the hypothesis
Two larger studies push the argument toward restraint. RACER-Knee randomised 339 patients and found no clinically meaningful 12-month Forgotten Joint Score advantage for Mako-assisted over conventional total knee replacement, with an adjusted mean difference of −1.5 and a 95% confidence interval from −7.5 to 4.5. Both arms initially targeted mechanical alignment, although surgeon-directed adjustments were permitted. In other words, the study tested whether the robotic pathway itself added enough value to matter in everyday recovery, and it did not show a meaningful advantage at one year.
RASKAL, a registry-nested 2 × 2 factorial trial that included 303 patients in its modified intention-to-treat analysis, compared robotic-assisted with computer-assisted surgery and functional with mechanical alignment. Neither robotic assistance nor functional alignment produced a significant advantage in KOOS-12 outcomes over its respective comparator through 2 years. No significant technology-by-alignment interaction emerged for that outcome, even though functional alignment required fewer soft-tissue releases. Fewer releases suggest a potentially more natural balancing strategy, but the reduction in surgical manipulation did not translate into a measurable patient-reported benefit within the follow-up window reported here.
What the registry comparison can and cannot answer
Registry analyses remain valuable because they reflect routine practice at scale, where surgeon experience, implant choice, and case mix are closer to daily reality than in tightly controlled trials. Mohammad et al. matched on annual surgeon caseload and excluded each surgeon’s first 10 robotic procedures in sensitivity analyses, steps that strengthen internal consistency. Even so, the pooled registry estimate still does not separate the contribution of the robot platform from the alignment target or balancing strategy. A Mako case, a functional alignment case, and a mechanically aligned case can all sit inside the same robotic umbrella while pursuing different biomechanical goals.
This is where revision endpoints become deceptively blunt. Early revision is an important safety outcome, but it is also a distant readout of a complex sequence involving pain, function, implant fixation, instability, infection, and surgeon decision-making. A platform that improves cut accuracy may still fail to change revision rates if the dominant drivers of early failure lie elsewhere. The registry result therefore weakens the claim that robotic assistance as presently deployed is producing broad, immediate outcome gains, while leaving open the possibility that specific combinations of platform, alignment target, and implant could perform differently.
Platform effects, alignment effects, and the missing interaction
The distinction between a robotic platform effect and an alignment effect is not semantic. It determines whether the technology itself is adding value or whether the apparent benefit comes from the surgeon choosing a different reconstruction philosophy once the robot is available. In practice, robotic systems can enable more consistent execution of a preferred alignment plan, but they do not prove that the plan is superior. The same is true in reverse: a better alignment concept may look impressive when paired with robotics, yet the improvement may depend on the philosophy rather than the hardware.
That problem is especially relevant for outcomes such as Forgotten Joint Score and KOOS, where patients report how the knee feels during everyday life rather than how precisely the components sit on a radiograph. Those measures should be sensitive to alignment strategy, soft-tissue balance, and implant behavior during gait. They are less likely to reward a technical refinement unless that refinement changes the mechanical environment of the joint in a way patients can actually feel. The available studies suggest that precise execution alone is not enough to guarantee a perceptible difference.
What future studies need to measure directly
Future registry-linked analyses should record the robotic platform, implant details, and intended alignment targets in a way that allows separate estimation of each component’s effect. Patient-reported outcomes and revision surveillance should remain central, but prespecified subgroup hypotheses are essential if investigators want to test whether any platform performs better under a given alignment strategy. The current evidence base also needs adequate power for interaction testing, because the most clinically interesting question may not be whether robotics helps in general, but whether a specific robot does better when paired with a specific biomechanical approach.
Longer-term follow-up will matter as well. Early function and radiographic precision may diverge from late survivorship, especially if a more anatomic alignment strategy changes wear patterns, ligament strain, or patient satisfaction in ways that only become visible over time. Until those data arrive, the existing trials support a restrained interpretation: robotic assistance can improve technical accuracy, but the incremental clinical benefit remains unproven when platform, alignment, and balancing strategy are mixed into the same comparison. The next step is not more enthusiasm for the category as a whole, but better separation of its moving parts.